Autologous ovarian tumor cell

Autologous ovarian tumor cells serve as a personalized therapeutic target and primary antigen source in the development of cancer vaccines and cellular immunotherapies. By harvesting malignant tissue directly from the patient during surgical debulking, researchers can capture the complete profile of patient-specific clonal neoantigens and tumor-associated antigens, which are often unique to the individual's disease [1, 3]. These cells are frequently modified ex vivo—using techniques such as haptenization or genetic engineering to express stimulatory cytokines like GM-CSF and knock down immunosuppressive factors like TGF-beta—to overcome the tumor's natural immune evasion mechanisms [4, 8]. Once reintroduced into the patient, these engineered cells prime the immune system, specifically activating T-cells to identify and destroy residual cancer cells throughout the body. This approach is primarily investigated as a maintenance therapy for advanced-stage ovarian cancer, showing particular clinical promise in patients with specific molecular profiles, such as those with homologous recombination proficient (HRP) status and high tumor mutational burden (TMB) [3, 7]. Compared to traditional chemotherapy, this cellular targeting strategy aims to provide a more durable and precise antitumor response with significantly lower systemic toxicity [8].

Other names

Autologous ovarian cancer cellPatient-derived ovarian tumor cellAutologous malignant ovarian tissueAutologous ovarian epithelial cancer cell

Autologous ovarian tumor cells serve as a comprehensive source of patient-specific clonal neoantigens and tumor-associated antigens (TAAs) for personalized immunotherapy. The primary mechanism involves using these harvested cells to educate the patient's adaptive immune system to recognize and attack malignant tissue. In advanced platforms like Gemogenovatucel-T, the cells are genetically engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) and inhibit furin-dependent production of immunosuppressive TGF-beta1 and TGF-beta2, thereby enhancing antigen presentation and T-cell activation in the tumor microenvironment [1, 3, 8].